直接抗病毒药物治疗前后HCV肝硬化患者亚临床心血管损伤的前瞻性研究
前瞻性研究纳入39例无心血管事件的HCV代偿期肝硬化患者,按年龄、性别和心血管危险因素匹配39例无肝病和心血管病的对照。基线时肝硬化患者整体纵向应变显著低于对照,脉搏波速度和β硬度指数显著高于对照;DAAs获得持续病毒学应答后随访9个月,三尖瓣环收缩期位移和侧壁E'速度较基线显著改善。
要点
- HCV肝硬化患者基线整体纵向应变显著低于对照,脉搏波速度和β硬度指数显著高于对照。
- 多因素回归分析中,糖尿病和HCV肝硬化是整体纵向应变的独立预测因素。
- DAAs获得持续病毒学应答后随访9个月,三尖瓣环收缩期位移和侧壁E'速度较基线显著改善。
核心结论
- HCV肝硬化患者存在显著的亚临床心脏和血管异常。
- 在DAAs实现病毒清除、生存与肝病进展关联减弱的背景下,心血管疾病负担可能发挥重要作用。
研究设计与样本
- 前瞻性研究,纳入39例无既往心血管事件的HCV肝硬化患者,按年龄、性别和心血管危险因素匹配39例无肝病和心血管病的对照。
- 患者和对照均接受基线超声心动图评估,包括整体纵向应变和颈动脉超声扫描。
- HCV肝硬化患者在DAAs获得持续病毒学应答后复查超声心动图和颈动脉超声。
主要发现
- HCV肝硬化患者基线整体纵向应变较对照显著降低:-18.1(16.3-20.5)vs -21.2(20.4-22.3),P < 0.001。
- HCV肝硬化患者脉搏波速度较对照显著升高:8.6(7.7-9.1)m/s vs 6.6(6.0-7.1)m/s,P = 0.0001。
- HCV肝硬化患者β硬度指数较对照显著升高:12.4(11.1-13.5)vs 8.6(8.0-9.2),P = 0.0001。
- 多因素回归分析中,糖尿病和HCV肝硬化是整体纵向应变的独立预测因素。
- 全部HCV肝硬化患者DAAs均获得持续病毒学应答;39例中32例(82%)随访9(8-10)个月,三尖瓣环收缩期位移较基线显著改善(P = 0.01),侧壁E'速度较基线显著改善(P = 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cirrhosis is associated with morpho-functional cardiovascular alterations. AIMS: To detect early features of cardiovascular damage in HCV-compensated cirrhotic patients using myocardial deformation indices and carotid arterial stiffness, and, further, to evaluate their short-term behaviour after HCV eradication with direct antiviral agents (DAAs). METHODS: Thirty-nine consecutive patients with HCV cirrhosis, without previous cardiovascular events, were studied and matched for age, gender and cardiovascular risk factors to 39 controls without liver or cardiovascular disease. Patients and controls underwent a baseline echocardiographic evaluation including global longitudinal strain and ultrasound scan of carotid arteries. HCV-cirrhotics were reassessed by echocardiography and carotid ultrasound after obtaining sustained virological response (SVR) on DAAs. RESULTS: HCV-cirrhotics showed at baseline a significantly reduced global longitudinal strain compared to controls -18.1 (16.3-20.5) vs -21.2 (20.4-22.3), P < 0.001. They also had a significantly higher pulse wave velocity 8.6 (7.7-9.1) m/s vs 6.6 (6.0-7.1) m/s, P = 0.0001, and β-stiffness index 12.4 (11.1-13.5) vs 8.6 (8.0-9.2) P = 0.0001. At multiple regression analysis, diabetes and HCV cirrhosis were independent predictors of global longitudinal strain. All HCV-cirrhotic patients had SVR on DAAs. Follow-up available in 32 of 39 (82%) at 9 (8-10) months showed a significant improvement of tricuspid annular plane systolic excursion (P = 0.01) and lateral E' velocity compared to baseline (P = 0.001). CONCLUSIONS: HCV-cirrhotics show a significant rate of subclinical cardiac and vascular abnormalities. At a time when their survival is less linked to progression of liver disease, due to viral eradication on DAAs, cardiovascular morbidity and mortality may take a significant role.
引用
- Novo G, Macaione F, Giannitrapani L, et al. Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. Aliment Pharmacol Ther. 2018. PMID: 30095177. doi:10.1111/apt.14934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。